LJAC
EPZM

L.J. Altfest & Co’s Epizyme, Inc EPZM Stock Holding History

L.J. Altfest & Co’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,079
Closed -$204K – 285
2020
Q3 		$204K Buy
17,079
+2,710
+19% +$36.3K 0.05% 215
2020
Q2 		$231K Buy
+14,369
New +$251K 0.07% 191

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

L.J. Altfest & Co's EPZM Position: Q4 2020 in Review

L.J. Altfest & Co sold out of Epizyme, Inc (EPZM) in Q4 2020, closing a stake of 17,079 shares — an estimated $204K sold.

L.J. Altfest & Co first reported a position in EPZM in Q2 2020 and held it in 2 quarters. The position peaked at $231K in Q2 2020. 137 funds tracked by Wall St. Rank hold EPZM as of Q4 2020.

  • L.J. Altfest & Co reported no remaining Epizyme, Inc position as of Q4 2020 after selling out during the quarter.
  • L.J. Altfest & Co sold 17,079 Epizyme, Inc shares in Q4 2020, an estimated $204K.
  • L.J. Altfest & Co first reported a position in Epizyme, Inc in Q2 2020 and held it in 2 quarters.
  • L.J. Altfest & Co's Epizyme, Inc position peaked at $231K in Q2 2020.
  • 137 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2020.

Based on L.J. Altfest & Co's 13F filing for Q4 2020, filed 21 Jan 2021.